In MEF2C+ AML, SIK inhibitors seem highly effective and represent a rare example of kinase inhibitors that indirectly inactivate this oncogenic MEF2C transcription factor (39, 40, 48). This evidence concerns the gene SIK1 and acute myeloid leukemia.